相似文献
1
Studies toward the duocarmycin prodrugs for the antibody prodrug therapy approach.
Tetrahedron Lett. 2009 Jun 1;50(24):2933-2935. doi: 10.1016/j.tetlet.2009.03.205.
2
In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy.
Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7528-33. doi: 10.1073/pnas.131187998. Epub 2001 Jun 12.
3
Asymmetric synthesis of a CBI-based cyclic N-acyl O-amino phenol duocarmycin prodrug.
J Org Chem. 2014 Oct 17;79(20):9699-703. doi: 10.1021/jo501839x. Epub 2014 Oct 3.
4
A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy.
J Mol Biol. 2003 Sep 26;332(4):889-99. doi: 10.1016/s0022-2836(03)00992-6.
5
Computational elucidation and validation of the three-dimensional structure of humanized aldolase catalytic antibody 38C2.
J Biomol Struct Dyn. 2021 Apr;39(7):2463-2477. doi: 10.1080/07391102.2020.1751290. Epub 2020 Apr 20.
6
Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation.
Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5584-9. doi: 10.1073/pnas.0700223104. Epub 2007 Mar 19.
7
Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer.
J Med Chem. 2012 Jan 26;55(2):766-82. doi: 10.1021/jm201284m. Epub 2012 Jan 5.
8
Synthesis and anticancer activity of benzoselenophene and heteroaromatic derivatives of 1,2,9,9a-tetrahydrocyclopropa[c]benzo[e]indol-4-one (CBI).
Org Biomol Chem. 2017 Feb 1;15(5):1198-1208. doi: 10.1039/c6ob02729f.
9
Synthesis and catalytic antibody functionalization of dendrimers.
J Am Chem Soc. 2001 Aug 29;123(34):8248-59. doi: 10.1021/ja001819f.
10
Synthesis, chemical properties, and biological evaluation of CC-1065 and duocarmycin analogues incorporating the 5-methoxycarbonyl-1,2,9,9a-tetrahydrocyclopropa.
J Org Chem. 2001 Apr 6;66(7):2207-16. doi: 10.1021/jo001772g.
引用本文的文献
1
Insights into Free Drug Release from Efficacious -Acyl -Aminophenol Duocarmycin Prodrugs.
ACS Chem Biol. 2025 Feb 21;20(2):442-454. doi: 10.1021/acschembio.4c00754. Epub 2025 Feb 9.
2
Rapid Construction of a Chloromethyl-Substituted Duocarmycin-like Prodrug.
Molecules. 2023 Jun 16;28(12):4818. doi: 10.3390/molecules28124818.
3
A five-membered lactone prodrug of CBI-based analogs of the duocarmycins.
Tetrahedron Lett. 2015 Jun 3;56(23):3101-3104. doi: 10.1016/j.tetlet.2014.11.038.
4
A fundamental relationship between hydrophobic properties and biological activity for the duocarmycin class of DNA-alkylating antitumor drugs: hydrophobic-binding-driven bonding.
J Med Chem. 2013 Sep 12;56(17):6845-57. doi: 10.1021/jm400665c. Epub 2013 Aug 29.
5
Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs.
J Med Chem. 2013 May 23;56(10):4104-15. doi: 10.1021/jm400413r. Epub 2013 May 10.
6
A novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct.
J Med Chem. 2012 Jun 28;55(12):5878-86. doi: 10.1021/jm300330b. Epub 2012 Jun 12.
7
Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.
Mol Pharm. 2012 Jan 1;9(1):168-75. doi: 10.1021/mp200434n. Epub 2011 Nov 22.
8
The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity.
ChemMedChem. 2011 Jan 3;6(1):54-9. doi: 10.1002/cmdc.201000478.
9
Design, synthesis, and evaluation of duocarmycin O-amino phenol prodrugs subject to tunable reductive activation.
J Med Chem. 2010 Nov 11;53(21):7731-8. doi: 10.1021/jm1010397.
本文引用的文献
1
Total synthesis and evaluation of iso-duocarmycin SA and iso-yatakemycin.
J Am Chem Soc. 2009 Jan 28;131(3):1187-94. doi: 10.1021/ja808108q.
2
Recent trends in targeted anticancer prodrug and conjugate design.
Curr Med Chem. 2008;15(18):1802-26. doi: 10.2174/092986708785132997.
3
Catalytic activity of certain antibodies as a potential tool for drug synthesis and for directed prodrug therapies.
Curr Med Chem. 2008;15(16):1606-15. doi: 10.2174/092986708784911533.
4
Duocarmycin-based prodrugs for cancer prodrug monotherapy.
Bioorg Med Chem. 2008 Jun 15;16(12):6312-8. doi: 10.1016/j.bmc.2008.05.009. Epub 2008 May 7.
5
Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation.
Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5584-9. doi: 10.1073/pnas.0700223104. Epub 2007 Mar 19.
6
Breaking the one antibody-one target axiom.
Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11009-14. doi: 10.1073/pnas.0603822103. Epub 2006 Jul 5.
7
Prodrugs of dynemicin analogs for selective chemotherapy mediated by an aldolase catalytic Ab.
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3095-9. doi: 10.1073/pnas.0307319101. Epub 2004 Feb 23.
8
Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2.
J Am Chem Soc. 2004 Feb 18;126(6):1726-31. doi: 10.1021/ja039052p.
9
Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5396-400. doi: 10.1073/pnas.0931308100. Epub 2003 Apr 17.
Zotero 插件